Shaochuan Liu

Tianjin, 300060, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

A senescence-associated gene signature predicts radiotherapy prognosis in non-small cell lung cancer and identifies CSF1 as a target to potentiate radioimmunotherapy.

A senescence-associated gene signature predicts radiotherapy prognosis in non-small cell lung cancer and identifies CSF1 as a target to potentiate radioimmunotherapy.

Journal: Biology direct
Published: February 07, 2026

PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib.

PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib.

Journal: Frontiers in oncology
Published: December 12, 2024

CK2B Induces CD8+ T-Cell Exhaustion through HDAC8-Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer.

CK2B Induces CD8+ T-Cell Exhaustion through HDAC8-Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 10, 2024

Multiomics profiling reveals the benefits of gamma-delta (γδ) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer.

Multiomics profiling reveals the benefits of gamma-delta (γδ) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer.

Journal: Journal for immunotherapy of cancer
Published: December 13, 2023

Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials.

Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials.

Journal: Journal of leukocyte biology
Published: October 15, 2023

Phosphoglycerate mutase 1 promotes breast cancer progression through inducing immunosuppressive M2 macrophages.

Phosphoglycerate mutase 1 promotes breast cancer progression through inducing immunosuppressive M2 macrophages.

Journal: Cancer gene therapy
Published: October 13, 2023

Novel strategies for cancer immunotherapy: counter-immunoediting therapy.

Novel strategies for cancer immunotherapy: counter-immunoediting therapy.

Journal: Journal of hematology & oncology
Published: January 18, 2023

Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib.

Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib.

Journal: Cancer medicine
Published: November 15, 2022

Rational pemetrexed combined with CIK therapy plus anti-PD-1 mAbs administration sequence will effectively promote the efficacy of CIK therapy in non-small cell lung cancer.

Rational pemetrexed combined with CIK therapy plus anti-PD-1 mAbs administration sequence will effectively promote the efficacy of CIK therapy in non-small cell lung cancer.

Journal: Cancer gene therapy
Published: June 29, 2022

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab.

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab.

Journal: Frontiers in oncology
Published: February 14, 2022

CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer.

CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer.

Journal: Cell death & disease
Published: January 22, 2022

Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma.

Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma.

Journal: Neoplasia (New York, N.Y.)
Published: February 04, 2021
Showing 1-12 of 17

Last Updated: 09/26/2026